CWS Financial Advisors LLC Invests $207,000 in Gilead Sciences, Inc. $GILD

CWS Financial Advisors LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 1,847 shares of the biopharmaceutical company’s stock, valued at approximately $207,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Colonial Trust Advisors raised its position in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. Cornerstone Select Advisors LLC raised its holdings in Gilead Sciences by 10.5% in the 1st quarter. Cornerstone Select Advisors LLC now owns 11,971 shares of the biopharmaceutical company’s stock valued at $1,341,000 after acquiring an additional 1,137 shares in the last quarter. Edgar Lomax Co. VA raised its holdings in Gilead Sciences by 84.2% in the 1st quarter. Edgar Lomax Co. VA now owns 231,390 shares of the biopharmaceutical company’s stock valued at $25,927,000 after acquiring an additional 105,800 shares in the last quarter. Korea Investment CORP raised its holdings in Gilead Sciences by 9.0% in the 1st quarter. Korea Investment CORP now owns 1,240,334 shares of the biopharmaceutical company’s stock valued at $138,979,000 after acquiring an additional 102,232 shares in the last quarter. Finally, Qtron Investments LLC raised its stake in Gilead Sciences by 35.7% in the first quarter. Qtron Investments LLC now owns 14,375 shares of the biopharmaceutical company’s stock valued at $1,611,000 after purchasing an additional 3,781 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. This trade represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock worth $12,349,790 over the last quarter. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Finally, Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research report on Friday, August 8th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $114.82.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $117.99 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The business has a 50-day moving average price of $111.98 and a two-hundred day moving average price of $108.64. Gilead Sciences, Inc. has a 1-year low of $73.27 and a 1-year high of $121.83. The company has a market cap of $146.40 billion, a P/E ratio of 23.50, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.